d419f463e9
- Source: inbox/queue/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
3.5 KiB
| type | domain | description | confidence | source | created | title | agent | sourced_from | scope | sourcer | supports | related | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| claim | health | Clinical recommendations for SCOFF questionnaire screening and monitoring of eating behaviors exist in academic literature but have not been adopted into mandatory prescribing protocols | proven | MDPI Nutrients review recommendations; absence from FDA labeling and professional society guidelines | 2026-05-04 | Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk | vida | health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md | structural | MDPI Nutrients |
|
|
Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
This review provides detailed clinical recommendations for eating disorder risk mitigation: (1) pre-treatment screening using SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation; (2) ongoing monitoring of eating behaviors, mood, and suicidal ideation with heightened vigilance during dose escalations; (3) multidisciplinary approach with psychological care, dietitian, and medical oversight rather than standalone medication; (4) preventive strategies introducing DBT/mindfulness before appetite suppression eliminates food-based coping. However, these recommendations exist only in academic literature. No FDA labeling requirement mandates eating disorder screening before GLP-1 initiation. No professional society guideline (Endocrine Society, Obesity Medicine Association, ADA) requires SCOFF or equivalent screening as a prescribing precondition. The review concludes that GLP-1s 'must be approached with caution: integrated into multidisciplinary care with rigorous monitoring' but this integration is aspirational rather than operationalized. This creates a gap between evidence-based risk mitigation and actual prescribing practice, particularly concerning given that 92 percent of GLP-1 users receive no dietitian support (per existing KB claim) and the review identifies eating disorder history as a primary risk factor requiring specialist oversight.
Supporting Evidence
Source: PMC/Journal of Clinical Medicine systematic review, 2025
Review explicitly states 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders specifically, and calls for pre/post-treatment psychological assessment and screening for high-risk ED patients before initiating, but notes these are recommendations not requirements.
Supporting Evidence
Source: VigiBase 2.06M reports, aROR analysis
VigiBase analysis quantifies eating disorder signal magnitude at aROR 4.17-6.80 (4-7x higher reporting odds), the highest psychiatric signal in the study. However, database lacked pre-existing psychiatric condition data, preventing distinction between medicine-induced reactions and indication bias—supporting screening recommendation but not mandate.